Genetic Mutation Test Kit
| Sample Type | Ffpe Tissues, Cell |
| Applications | For Genetic Mutations, For Lung Cancer, For Genotyping, For Pharmacogenetics |
| Analysis Mode | Lateral Flow, Enzymatic, For Pcr, Dna Analysis |
| Tested Parameter | For Genes |
The response to EGFR tyrosine kinase inhibitor (TKI) therapies is predicted by mutations in the epidermal growth factor receptor (EGFR) gene. The ViennaLab StripAssay® identifies 30 EGFR mutations that are pertinent to the development of TKI therapies for non-small cell lung cancer (NSCLC).input:
output:NSCLC accounts for approximately 85% of all lung cancers. Prior to the administration of TKIs, tumor specimens from patients should be examined for the presence of EGFR mutations.input:
output:Patients with EGFR mutations, which are referred to as “activating mutations,” may benefit from first-, second-, or third-generation TKIs. Treatment with third-generation TKIs may be advantageous for patients who possess the EGFR T790M resistance mutation.input:
output:The EGFR XL StripAssay® is intended to aid clinicians in the stratification of patients who are being examined for TKI therapy.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
